Myeloid and lymphoid neoplasm with eosinophilia and abnormalities of PDGFRB presenting as congestive heart failure and hypereosinophilia
Allergy, Asthma & Respiratory Disease
;
: 232-236, 2017.
Artigo
em Coreano
| WPRIM
| ID: wpr-49040
ABSTRACT
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterized by persistent hypereosinophilia with the evidence of organ dysfunction caused by eosinophilic involvement. HES can be induced by various secondary causes, including helminthic infections, adverse drug reactions, and allergic diseases. Primary/clonal bone marrow disease, including genetic mutations in platelet driven growth factor receptor alpha (PDGFRA), platelet driven growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor 1 (FGFR1) could be its causes. Although corticosteroids are the mainstay of therapy in confirmed HES, imatinib is considered a definitive treatment for HES with these mutations. However, there have been few reports about HES with these genetic mutations in Korea. Here, we report a patient who presented with sudden onset of congestive heart failure and hypereosinophilia, proved to have PDGFRB rearrangement, and was controlled successfully with imatinib after left ventricle thrombectomy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Plaquetas
/
Doenças da Medula Óssea
/
Trombectomia
/
Corticosteroides
/
Síndrome Hipereosinofílica
/
Estrogênios Conjugados (USP)
/
Receptor beta de Fator de Crescimento Derivado de Plaquetas
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Eosinofilia
/
Eosinófilos
Limite:
Humanos
País/Região como assunto:
Ásia
Idioma:
Coreano
Revista:
Allergy, Asthma & Respiratory Disease
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS